MX382673B - Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico. - Google Patents

Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.

Info

Publication number
MX382673B
MX382673B MX2017003387A MX2017003387A MX382673B MX 382673 B MX382673 B MX 382673B MX 2017003387 A MX2017003387 A MX 2017003387A MX 2017003387 A MX2017003387 A MX 2017003387A MX 382673 B MX382673 B MX 382673B
Authority
MX
Mexico
Prior art keywords
vegf
colorectal cancer
metastatic colorectal
predictive
subjects
Prior art date
Application number
MX2017003387A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003387A (es
Inventor
Bo Gao
Israel Lowy
Tasha Nicholle Sims
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017003387A publication Critical patent/MX2017003387A/es
Publication of MX382673B publication Critical patent/MX382673B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57419Specifically defined cancers of colon
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475Assays involving growth factors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2017003387A 2014-09-16 2015-09-10 Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico. MX382673B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462051091P 2014-09-16 2014-09-16
US201562099630P 2015-01-05 2015-01-05
PCT/US2015/049279 WO2016044041A1 (en) 2014-09-16 2015-09-10 Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer

Publications (2)

Publication Number Publication Date
MX2017003387A MX2017003387A (es) 2018-01-30
MX382673B true MX382673B (es) 2025-03-13

Family

ID=54207741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003387A MX382673B (es) 2014-09-16 2015-09-10 Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.

Country Status (12)

Country Link
US (2) US10525104B2 (cg-RX-API-DMAC7.html)
EP (1) EP3194974B1 (cg-RX-API-DMAC7.html)
JP (1) JP6692358B2 (cg-RX-API-DMAC7.html)
KR (1) KR102471057B1 (cg-RX-API-DMAC7.html)
CN (1) CN107076749B (cg-RX-API-DMAC7.html)
AU (1) AU2015318207B2 (cg-RX-API-DMAC7.html)
CA (1) CA2960890A1 (cg-RX-API-DMAC7.html)
EA (1) EA036671B1 (cg-RX-API-DMAC7.html)
IL (1) IL250905B (cg-RX-API-DMAC7.html)
MX (1) MX382673B (cg-RX-API-DMAC7.html)
WO (1) WO2016044041A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201701664B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014158287A2 (en) 2013-03-14 2014-10-02 Otraces Inc. A method for improving disease diagnosis using measured analytes
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
EP3405896A4 (en) 2016-01-22 2019-09-25 Otraces Inc. SYSTEMS AND METHOD FOR IMPROVED DIAGNOSIS OF ILLNESSES
AU2018245602B2 (en) 2017-03-31 2021-07-22 Hirotsu Bio Science Inc. Method for predicting therapeutic effect and/or recurrence monitoring in cancer patients
EA202091786A1 (ru) 2018-01-26 2020-10-20 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Способы и композиции для лечения ангиогенных расстройств с применением агентов против фрэс
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
WO2020165483A1 (es) * 2019-02-15 2020-08-20 Universidad de Córdoba Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos
EP3997704A4 (en) * 2019-07-13 2023-07-19 Otraces Inc. IMPROVEMENT OF DIAGNOSIS FOR VARIOUS DISEASES USING ACTIVE PROTEINS OF A TUMOR MICROAREA
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
US20220390456A1 (en) * 2019-10-17 2022-12-08 Board Of Regents, The University Of Texas System Small extracellular vesicle-associated vegf as a predictor for therapeutic responses
MX2022006241A (es) 2019-11-25 2022-08-22 Univ California Inhibidores de vegf de accion prolongada para la neovascularizacion intraocular.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN101283280A (zh) * 2005-08-18 2008-10-08 Zadec私人有限公司 用于诊断结直肠癌的蛋白质标记和所述标记作为所述癌症类型治疗的药物靶点的用途
EP2464366A2 (en) * 2009-08-14 2012-06-20 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
SG10201500479XA (en) * 2010-01-19 2015-03-30 Hoffmann La Roche Tumor Tissue Based Biomarkers For Bevacizumab Combination Therapies
MX2013000676A (es) * 2010-07-19 2013-02-27 Hoffmann La Roche Metodo para identificar pacientes con probabilidad incrementada de responder a una terapia anti-cancer.
JO3283B1 (ar) * 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)

Also Published As

Publication number Publication date
IL250905A0 (en) 2017-04-30
US20200129589A1 (en) 2020-04-30
AU2015318207A1 (en) 2017-04-06
MX2017003387A (es) 2018-01-30
JP6692358B2 (ja) 2020-05-13
US10525104B2 (en) 2020-01-07
AU2015318207B2 (en) 2021-11-04
US11439683B2 (en) 2022-09-13
ZA201701664B (en) 2018-05-30
EP3194974B1 (en) 2019-10-23
US20170281725A1 (en) 2017-10-05
JP2017530372A (ja) 2017-10-12
IL250905B (en) 2019-12-31
KR102471057B1 (ko) 2022-11-28
CA2960890A1 (en) 2016-03-24
EP3194974A1 (en) 2017-07-26
CN107076749A (zh) 2017-08-18
KR20170055972A (ko) 2017-05-22
EA036671B1 (ru) 2020-12-07
EA201790549A1 (ru) 2017-07-31
WO2016044041A1 (en) 2016-03-24
CN107076749B (zh) 2020-12-29

Similar Documents

Publication Publication Date Title
MX382673B (es) Biomarcadores predictivos y para prognosis relacionados con terapia anti-angiogénica de cáncer colorrectal metastasico.
MX2017008421A (es) Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
CY1122233T1 (el) Μεθοδος για την προβλεψη του αποτελεσμaτος μιας θεραπειας με αφλιβερσεπτη ενος ασθενους με υποψια οτι πασχει απο καρκινο
BR112017020893A2 (pt) método para o tratamento de câncer
CR20170297A (es) Método para la cuantificación absoluta de péptidos cancerosos restringidos a hla que son procesados de forma natural
BR112017009728A2 (pt) anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, método para produzir o anticorpo, composição, usos de um anticorpo e métodos de tratamento de um distúrbio
EA201790019A1 (ru) Способ выбора персонализированной трехкомпонентной терапии для лечения рака
EA201791578A1 (ru) Панель биомаркеров для обнаружения рака
PE20160192A1 (es) Composiciones y metodo para tratar condiciones asociadas con el complemento
MX392040B (es) Estandares de antigeno prostatico y sus usos.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
BR112017008799A2 (pt) composições de apilimod e métodos de uso das mesmas no tratamento de câncer renal
EP3647788A4 (en) BIOMARKER FOR THE DETECTION OF COLORECTAL CANCER
MX384423B (es) Biomarcadores para la respuesta a inhibidores del mejorador del homólogo 2 de zeste (ezh2).
CL2015000192A1 (es) Método de seleccion de un sujeto que padece un tumor maligno para tratamiento con inhibidor de jak/stat que comprende determinar nivel de expresión de biomarcadores.
MX2016015163A (es) Biomarcadores mit y metodos para su uso.
DK3250708T3 (da) Biomarkører for kolorektal cancer-relaterede sygdomme
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
EA201891478A1 (ru) Способы и композиции для оценки риска возникновения рака
MX381948B (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
MA40636A (fr) Procédés pour détecter le cancer de la prostate
BR112016015595A2 (pt) métodos de determinação de câncer de pulmão
MX2015013197A (es) Biomarcadores de la respuesta farmacodinamica tumoral.
EP3111223C0 (en) LUNG CANCER BIOMARKERS, METHODS AND KITS THEREOF
WO2018074865A3 (ko) 유방암 예후 예측용 조성물 및 방법